Sui Xinbing, Xu Yinghua, Wang Xian, Han Weidong, Pan Hongming, Xiao Mang
Department of Medical Oncology, Sir Run Run Shaw Hospital, Zhejiang University , 310027 Hangzhou, China.
Biomedical Research Center and Key Laboratory of Biotherapy of Zhejiang Province , 310027 Hangzhou, China.
Mol Pharm. 2015 Nov 2;12(11):3783-91. doi: 10.1021/acs.molpharmaceut.5b00577. Epub 2015 Oct 2.
Metformin, a biguanide derivative that is widely used for treating type 2 diabetes mellitus, has recently been shown to exert potential anticancer effects. Many retrospective data and laboratory studies suggest the idea that metformin has antineoplastic activity, but some other studies reach conflicting conclusions. Although the precise molecular mechanisms by which metformin affects various cancers have not been fully elucidated, activation of AMPK-dependent and AMPK-independent pathways along with energy metabolism aberration, cell cycle arrest and apoptosis or autophagy induction have emerged as crucial regulators in this process. In this Review, we describe the role of metformin in the prevention and treatment of a variety of cancers and summarize the molecular mechanisms that are currently well documented in the ability of metformin as an anticancer agent. In addition, the scientific and clinical hurdles regarding the potential role of metformin in cancer will be discussed.
二甲双胍是一种广泛用于治疗2型糖尿病的双胍衍生物，最近已显示出具有潜在的抗癌作用。许多回顾性数据和实验室研究表明二甲双胍具有抗肿瘤活性，但其他一些研究得出了相互矛盾的结论。尽管二甲双胍影响各种癌症的确切分子机制尚未完全阐明，但AMPK依赖性和非依赖性途径的激活以及能量代谢异常、细胞周期停滞和凋亡或自噬诱导已成为这一过程中的关键调节因素。在本综述中，我们描述了二甲双胍在预防和治疗多种癌症中的作用，并总结了目前关于二甲双胍作为抗癌药物能力的充分记录的分子机制。此外，还将讨论关于二甲双胍在癌症中潜在作用的科学和临床障碍。
